Triple
T7113631
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Bezos Expeditions |
E165762
|
entity |
| Predicate | notableInvestmentIn |
P17330
|
FINISHED |
| Object | Juno Therapeutics |
E387620
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Juno Therapeutics | Statement: [Bezos Expeditions, notableInvestmentIn, Juno Therapeutics]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Juno Therapeutics Context triple: [Bezos Expeditions, notableInvestmentIn, Juno Therapeutics]
-
A.
Juno Therapeutics
chosen
Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
-
B.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
C.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
D.
Acorda Therapeutics
Acorda Therapeutics is a biopharmaceutical company specializing in therapies for neurological disorders, particularly multiple sclerosis and other central nervous system conditions.
-
E.
Ariad Pharmaceuticals
Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c6888120f081908f8f01b201dc4a4c |
completed | March 27, 2026, 1:39 p.m. |
| NER | Named-entity recognition | batch_69c6e7759a048190815689298befa8d7 |
completed | March 27, 2026, 8:24 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c79cbc35d48190974e207eb98dcbe3 |
completed | March 28, 2026, 9:17 a.m. |
Created at: March 27, 2026, 2:43 p.m.